Vision is one of our most important senses. It has
always been vital, and is even more so in todays, "visual information
age." Even mobile phones, formerly the quintessential auditory devices,
have become more visual tools. Loss in vision is the number one fear when it
comes to age-related health matters. Even moderate visual problems can
significantly reduce a person’s productivity, mobility and independence.
As a specialized pharmaceutical company engaged in the ophthalmic field, Santen has established a paramount position in Japan's prescription ophthalmic pharmaceutical market and has expanded into the global market. Santen has been present in Europe for nearly 20 years and is continuing to strengthen its position in further countries so that all patients and health care professionals can have access to our innovative treatments.
We have the ambition to become a European leader in ophthalmology.
Our priority is to develop and acquire new and better solutions that respond to the needs of both patients and healthcare professionals. Santen’s activities primarily focus on ocular surface disorders including dry eye, glaucoma, retina and certain orphan eye diseases.
Research-based, Santen is dedicated to develop innovative therapeutic solutions to treat eye diseases in its four research centers based in Japan, USA, Finland and France.